Illumina (ILMN) investor relations material

Product innovation and roadmap

• Highlighted NovaSeq X platform's success and ongoing innovation, including new flow cells for both high and low capacity applications.

• Announced Q70 quality scores, enabling high-sensitivity MRD applications and faster turnaround times, especially valued in academic research.

• Launched TruPath (formerly Constellation), a technology combining short and long read sequencing, offering whole genome prep in 10 minutes at a $395 price point.

• Roadmap includes multiplexing for TruPath, scaling from 16 to 96 samples per run over 18 months, further reducing costs.

• Spatial technology advancements allow analysis of whole slide tissues, with early access generating strong customer interest and broader applications expected within six months.

Competitive landscape and market positioning

• Emphasized differentiation from competitors by focusing on quality and end-to-end solutions rather than just sequencing cost.

• Noted Roche's new technology has a different workflow, challenges in library prep, and a pricing model requiring high throughput, limiting its applications.

• Sequencing is not commoditized; complexity and workflow integration remain key differentiators.

• Counting applications addressed by competitors represent a small market segment (<$100M), with library prep costs outweighing sequencing costs.

• Acquisitions like Fluent and SomaLogic aim to drive down total workflow costs and enhance elasticity in research applications.

Financial guidance and growth outlook

• Organic growth guidance for 2026 is 2–4% ex-China, 1–3% including China, with clinical business expected to outpace research.

• Operating margin targeted to reach 26% with continued improvements, and EPS growth expected to remain in double digits, despite SomaLogic acquisition headwinds.

• Clinical consumables projected to grow 11–15%, with some conservatism due to ongoing pricing headwinds and macroeconomic uncertainty.

• Oncology remains the main growth driver in clinical NGS, with therapy selection dominant, but MRD and early cancer detection gaining momentum.